Damon Race/LinkedIn
Jun 25, 2026, 15:28
Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared a post on LinkedIn:
“Met up with my friends from ReciPharm Advanced Bio at BIO International 2026.
ReciPharm is a wonderful partner in our efforts to advance GENV-HEM, the first gene therapy with durable expression biology for patients with hemophilia A with or without inhibitors.
A special thank you to Greg Behar and Jhomar Marquez.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!